Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis

Inclusion Criteria: * Be at least 18 years of age and of either sex. * Subjects must have clinical evidence of interdigital tinea pedis of one or both feet characterized by: (i) moderate erythema, (ii) scaling and (iii) mild pruritis. * Have microscopic evidence (positive KOH) of the presence of fungi. Evaluable subjects must have a positive KOH and a fungal culture positive for a dermatophyte in the skin scrapings taken at the Baseline Visit. Subjects with a positive KOH may be entered into the study pending the results of the fungal culture * Be willing and able to give informed consent/assent or have their parent/guardian do so, if applicable. * Be willing and able to use the assigned study medication as directed and to commit to all follow-up visits for the duration of the study. * Be in good health and free of any disease or physical condition which might, in the Investigator's opinion, expose the subject to an unacceptable risk by study participation. * Females must be non-pregnant, non-lactating and not intending to become pregnant during the course of the study. Exclusion Criteria: * Is pregnant, nursing or planning a pregnancy during the study. * Has used topical antifungals or topical corticosteroids on the feet within 4 weeks prior to the start of the study. * Has received systemic antifungal therapy within 4 weeks prior to the start of the study medication. * Has used systemic antibacterials or systemic corticosteroids within 4 weeks prior to the start of the study. Systemic corticosteroids do not include intranasal, inhaled, and ophthalmic corticosteroids used for the management of allergies, pulmonary disorders or other conditions. * Has a history of uncontrolled diabetes mellitus or is immunocompromised (due to disease, e.g., HIV, or medications). * Has concurrent tinea infection e.g. Tinea Versicolor, Tinea Cruris, Moccasin-type Tinea Pedis, etc. (in the opinion of the Investigator). * Onychomycosis, involving ≥ 20% of the area of either great toenail or involvement of more than five toenails in total. * Has any other skin disease which might interfere with the evaluation of tinea pedis. * Is currently enrolled in an investigational drug or device study. * Has received an investigational drug or treatment with an investigational device within 30 days prior to entering this study. * Is unreliable, including subjects with a history of drug or alcohol abuse. * Has known hypersensitivity to any of the components of the study medications.